新股消息 | 丹诺医药港股IPO及境内未上市股份“全流通”获中国证监会备案

智通财经02-09

智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过12,498,400股境外上市普通股并在香港联合交易所上市。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。招股书显示，丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610862026?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-09 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610862026","market":"hk","top_or_hot":-1,"title":"新股消息 | 丹诺医药港股IPO及境内未上市股份“全流通”获中国证监会备案","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过12,498,400股境外上市普通股并在香港联合交易所上市。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。招股书显示，丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1403069.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 丹诺医药港股IPO及境内未上市股份“全流通”获中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 丹诺医药港股IPO及境内未上市股份“全流通”获中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 14:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1403069.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过12,498,400股境外上市普通股并在香港联合交易所上市。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。招股书显示，丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1403069.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1403069.html","article_id":"2610862026","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610862026","pubTimestamp":1770617856,"columns":[{"name":"新股","id":7,"label_key":null}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。利用这种独特的多靶点机制，利福特尼唑有望克服抗菌药物耐药性这一重要且日益严重的全球挑战。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159776":"医药港股","06872":"丹诺医药-B"},"translate_title":"New stock news | Dannuo Pharmaceutical's Hong Kong stock IPO and domestic unlisted shares \"full circulation\" were filed by the China Securities Regulatory Commission","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159776":1.5,"06872":2},"content_text":"智通财经APP获悉，2月6日，中国证监会国际合作司发布《关于丹诺医药(苏州)股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过12,498,400股境外上市普通股并在香港联合交易所上市。公司49名股东拟将所持合计43,472,926股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。招股书显示，丹诺医药于2013年注册成立，是一家临近商业化阶段的生物科技公司，专注于发现、开发及商业化差异化的创新药产品，以解决细菌感染及细菌代谢相关疾病领域的未被满足临床需求。凭借自主开发的多靶点偶联分子技术，公司致力于为患者提供最佳治疗方案，以克服传统治疗的局限性并改善患者预后。截至最后实际可行日期，公司已建立一条由七项创新资产组成的差异化管线，包括三项核心产品：即利福特尼唑(TNP-2198)，是全球首个且唯一治疗幽门螺杆菌(“幽门螺杆菌”)感染的新分子实体(“NME”)候选药物;利福喹酮(TNP-2092)注射剂，一款潜在首创三靶点治疗植入体相关细菌感染的候选药物;及TNP-2092口服制剂，全球首个用于治疗肠道菌群代谢相关疾病的多靶点候选药物。核心产品利福特尼唑(TNP-2198)是由利福霉素药效团和硝基咪唑药效团构建的稳定偶联药物。通过抑制RNA聚合酶和硝基还原酶激活产生高活性物质实现杀菌作用，对微需氧菌和厌氧菌具有协同双重作用机制。利用这种独特的多靶点机制，利福特尼唑有望克服抗菌药物耐药性这一重要且日益严重的全球挑战。作为三联疗法的一部分，与目前指南推荐的一线治疗方案铋剂四联疗法(“BQT”)相比，利福特尼唑在疗效、安全性、临床应用和患者潜在依从性方面具有显著优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610862026","isCrawlerRequest":true}